



Leaving no cancer behind

**Real-Time intraoperative precision
Cancer cells detection**

**Investor Presentation
October 2025**

Forward looking statement

The information and projections provided in this presentation may include forward-looking statements with respect to plans, projections or future performance of the Company, the occurrence of which involves certain risks and uncertainties, some of which may not be under the control of Nutek , including, but not limited to, changes in regulatory environment, Nutek's success in implementing its research, development, sales, marketing and manufacturing plans, protection and validity of patents and other intellectual property rights, the impact of currency exchange rates and the effect of competition. Additionally, certain solutions or applications for Nutek's products, included in this presentation, may not yet be commercially available and/or regulatory cleared for marketing.

Any cancer surgery
ends up with one critical
question on surgeon's mind

Did I remove all the cancer ?

Surgeons currently lack real-
time information to confirm
complete tumor removal

leading to repeated
surgeries and billions \$
healthcare costs each year



Current procedure

Operation Room



Surgeons rely on subjective judgment no real-time detection



Excised tumor is marked for orientation and sent to pathology



Pathologist decides where to sample the excised tumor for margins cancer assessment

Only ~1% of margins are examined !!

Post Operation



Histopathology analysis of the selected samples

Pathology results



Cancer free margins or

Cancer found

= >

Call back patient for reoperation

←===== ~ 10 days =====→

Need for real-time , precise intra-operative residual cancer tissue detection

Problem

Surgeons rely on subjective judgment during operations

No precise real-time detection tools

Impact

Up to 36% of breast cancer patients require reoperation [1]

1 Million breast cancer reoperation annually [2]

\$10.8B annual healthcare costs globally [3]

Consequence

Missed cancer tissue = recurrence, distress, repeat surgery & huge healthcare costs

OUR AMBITION

Revolutionize surgical
oncology by pioneering
in-vivo real-time cancer
cells precision detection

No more guesswork and uncertainty


Our solution – the Rainbow Probe

- ✓ Scans and analyses 100% of the operation cavity with superior precision, where only ~ 1% of the excised tumor margins are analysed at pathology (Golden Standard)
- ✓ Leaves no hidden-remaining cancer tissue on the patient's body
- ✓ Surgeon gets indication within 2-3 seconds if clear or cancer found within the scanned area
- ✓ Scanning an entire cavity may add up to ~5 min to the surgery time
- ✓ Doesn't affect any other surgical or hospital's procedures
- ✓ Workflow compatible

Operation Room



Surgeons removes the tumor based on standard procedures



Rainbow Probe scans 100% of operation cavity on the patient's body

Detects and guides the surgeon to remaining cancer tissue for further removal

Guesswork and uncertainty are replaced with data-driven precise analysis

NUTEK's Team

Experienced in Oncology, Hyperspectral Technology and Med Tech global market

Advisory Board



Prof. Leonard Lane
University of California
Irvine USA
Emeritus Continuing
Lecturer global
Strategy and
Entrepreneurship



Prof. Lars P. Kamolz
Med. Uni. Graz
Head of University Surgery
Clinic & Dep. for Plastic,
Aesthetic and oncoplastic
Reconstructive Surgery
Medical University
Innovation Manager



Wesley I Paul
finance and technology professional with over 50 years
industry experience.
Worked at Exxon and JPMorgan the latter for 25 years
where he was a Managing Director & Global Head of
Investments.
Chaired and sat as a Board or Advisory Board Member
for several institutions including national museums,
think tanks, universities and conservation charities

Management Team



Steven Eitan
Active Chairman

- ✓ A seasoned global business leader with over 35 years of experience as CEO, CFO, and strategic advisor.
- ✓ Brings expertise in healthcare, Medical Devices and technology.
- ✓ Conducted business across North America, Europe, LATAM, Asia, Australia, and Africa,



Dov Cohen
Co-Founder, CEO

- ✓ Experienced leader of teams developing multi-disciplinary national airborne programs, EW, Radar and C4ISR,
- ✓ Director of Space Systems,
- ✓ Corporate Director of Business Development at Israel Aerospace Industries.
- ✓ Led development of Hyper Spectral remote sensing applications



Ofer Braun
Co-Founder, CTO

- ✓ Expert in the design and production of optical medical devices systems.
- ✓ Former Director of Space Hyper-spectral Imaging at Elbit Systems.
- ✓ Successfully led the development and deployment of unique optical and hyperspectral, space and airborne cameras and sensors.



Prof. Md. Hanoch Kashtan
Co-Founder, Medical Director

- ✓ Director of Surgery at ASSUTA Medical Centre, Former Director of Surgical Division at Belinson Hospital
- ✓ Surgical Oncologist with >30 years of experience
- ✓ Chair Scientific Council of the Israel Medical Association, and Member of the European Society of Surgical Oncology (ESSO).
- ✓ Founder of Medical Device companies. Wide international medical network



OUR MISSION

Ensure complete tumor removal in first surgery by harnessing advanced hyperspectral imaging and AI-driven technology

Huge global market opportunity

Initial focus - Breast cancer surgical oncology

- Breast cancer: **2.3 million** new cases annually [1]
- 17 million cancer patients undergo ~45 million operations each year (**~2.6 surgeries per patient**) [2]
- **~6 million** Expected breast cancer surgeries per year

Rainbow probe's design enables expansion to :

- Minimally invasive, Endoscopic, Laparoscopic and Robotic surgical procedures
- Other cancer types : Pancreas, Brain and Liver
- Potential integration with robotic systems (e.g., Da Vinci, Medtronic)



AI Cancer Tumor Margin Detection Device

Est. 2033

\$ 6 B [3]
CAGR 17.6%



Real Time Image Guided Surgery

Est. 2034

\$ 20.5 B [4]
CAGR 9.8%

[1] Globocan 10-12-2023

[2] Series on The Lancet Oncology Commission on Global Cancer Surgery—Action 1: Clinical Care and Access to Cancer Surgery Springer Nature , November 2024

[3] DATA INTELO -AI Tumour Margin Detection Device Market Outlook Estimated~\$6B in 2033 with 17.6% CAGR
<https://dataintel.com/report/ai-tumor-margin-detection-device-market>
Out of total Oncology Devices market of \$342 B in 2029 with CAGR of 17.8%
<https://www.thebusinessresearchcompany.com/report/oncology-devices-global-market-report>

[4] <https://www.precedenceresearch.com/image-guided-surgery-devices-market>

First real-time in-vivo cancer detection hyperspectral imaging and AI system

Hyper-Spectral Imaging (HSI)




Light interacts with tissues through absorption, reflection, and scattering, which vary depending on their bio-chemical composition and pathology



HSI is an advanced Imaging technique that captures the reflected light across a wide range of wavelengths within the electromagnetic spectrum and process it using AI




AI/ML identifies unique spectral signatures - "Fingerprints" of materials, highly effective for applications such as discriminating cancer from healthy tissues



NUTEK's unique implementation

- ✓ **Spatial resolution of 10μm pixel size**, suitable for histopathology image analysis
- ✓ **Spectral resolution of 5 nm**. enables high accuracy of the bio-markers identification
- ✓ **Unmatched precision**
- ✓ **Combining Image and Spectral analysis at pixel level** assures the highest discrimination accuracy of Cancer and Healthy tissue, using AI based algorithms
- ✓ **Adaptable to MIS, Endoscopic, and Robotics**
- ✓ **Provides real-time visualization on a compact surgeon-friendly display**



Enables surgeons to clearly distinguish healthy vs. cancerous tissue during surgery

NUTEK Product

Real-Time Cancer Detection



Seamless integration into surgical workflows for precise tumor delineation.

Adaptive Design for Versatile Surgery



Features a disposable scanning head adaptable to various surgery geometries and minimally invasive applications

Advanced Imaging Capabilities



Utilizes hyperspectral imaging technology powered by AI, offering personalized, patient-specific analysis during surgeries

Conceptual Video – watch how it works



https://www.youtube.com/watch?v=MPb-ESxNL_c



The Rainbow Probe characteristics

Intraoperative

- ✓ In-Vivo Detection of cancer tissues during operation
- ✓ scans on the patient's body, real-time healthy and cancer tissue discrimination
- ✓ Minimally affected workflow ~2 sec per scan, ~5 min total cavity scan



Guided Procedure

- ✓ Surgeon guidance, on the patient's body.
- ✓ Seamless workflow integration during surgery



Hyperspectral imaging technology powered by AI

- ✓ AI-based algorithms.
- ✓ Resolutions : Spatial - 10µm, Spectral – 5nm
- ✓ Possible engagement of a-priori data from pre-operation biopsy



Label Free Solution

- ✓ No agent injection needed
- ✓ Non label spectral analysis



Built by and for Surgeons

- ✓ Handheld device, small touchscreen, minimal OR space occupied
- ✓ Disposable scanning head enables Minimal Invasive and Robotic surgery's applications



Personalized, patient-specific

- ✓ Analysis is done with respect to the patient own healthy tissue does not depend on data from other patients



Next Generation Surgical Applications

Image guided surgical navigation

- ✓ Endoscopic procedures
- ✓ Robotic applications
- ✓ Minimal invasive surgeries



Real-Time Complimentary Surgical Info.

- ✓ Perfusion imaging
- ✓ Identify nerves and blood vessels
- ✓ Tumor detection




Quantitative data collection

- ✓ Images and signatures collected over time and human diversity
- ✓ Complements the Digital Pathology with the spectral domain







NUTEK's In-Vivo Rainbow Probe VS. Ex-Vivo intraoperative competition

	 NUTEK <small>Insight Beyond Visible</small>	Frozen Section	Margin Probe	Clear Cut	Perimeter
Technology	Hyperspectral Scanning Imaging	Histopathology	RF spectrum Bio-Impedance	Small scale MRI	Optical Coherent Tomography
Turn around time	2-3sec /scan <5min / cavity	20-45 min Per slide	< 5min	< 5min	< 5min
Surgeon guidance to the remaining cancer tissue in the patient's cavity	✓	✗	✗	✗	✗
Surgical surface coverage	100%	1-5%	60-80%	60-80%	60-80%
Agnostic to tissue type / density	✓	✗	✗	✗	✓
Affordable • Fix / Per surgery cost USD	14.5K\$ / 950\$	200-600\$ per slide	25-30K\$ / 1-1.5K\$	100-200K\$ / 500\$	150-250K\$ / none

NUTEK provides outmost accuracy at affordable price

In-Vivo competitive landscape

	 NUTEK Insight Beyond Visible	 HYPERVISION SURGICAL imec DIASPECTIVE VISION	 Quest medical imaging LUMICELL	 reveal SURGICAL	MasSpec Pen
Technology	Hyperspectral scanning imaging	HSI Starring Camera	Fluorescence Agent injection cancer visual view	Raman Spectroscopy Single point at a time	Mass Spectroscopy Single point at a time
Spatial resolution • Cancer cell size 10-20µm	10µm	50-100µm	50-100µm	1-5µm	1mm
Accurate cancer full- boundaries detection • Fusing tissue Image and spectral combination analysis	✓	✗	✗	✗	✗
Surgeon / Robotic guidance • Minimal collateral damage	✓	✗	✗	✗	✗
Label Free Solution	✓	✓	✗	✓	✓
Affordable • Fix / Per surgery cost USD	14.5K\$ / 950\$	250-400K\$ / 1-2.5K\$	100-150K\$ / 1-2K\$	100-300K\$ / <1K\$	250-400K\$ / <1K\$

NUTEK provides outmost accuracy at affordable price

Development status & key achievements



Animal Experiment, In-Vivo / Ex-Vivo ,



Proof Of Concept, Human Breast Cancer Ex-Vivo, using V1 prototype

- ✓ Spectral Samples : **939**, Sensitivity : **93.91%**, Specificity : **95.17%**
- ✓ AI-Based Algorithm Development



Development of Prototype with same performance as final product, MVP (TRL 6)

- ✓ Human Breast Cancer, experiment instrument
 - ✓ Data-Block extraction, enables AI algorithms earlier development
- Ready for next Experiment agreements finalized and Ethical (Helsinki) committee consent received at a Major Hospital



Complete optical design of the final product

- ✓ Enables initiating patents applications
- ✓ Major risk reduction



Patent Pending




Austrian subsidiary NUTEK AT GmbH, gateway to the EU




Strategic Cooperation with the Medical University of Graz



FFG
Forschung wirkt.



Breast cancer - path forward



TRL – Technology Readiness Level (EU definition)

MVP – Minimum Viable Product

★ – According to Hogan Lovells assessment

Pricing, business model & revenue forecast




Price per Surgery

Disposable scanning head
950\$

Price per OR

Reusable Handle
14,500\$

Yearly Net Revenue (In M USD)



Value Proposition Highlights

- Saving per repeated surgery 20-70K \$ or
- 10Y cost to insurer due to recurrence 200-500K \$

- Breast Cancer application
- Global Markets : US, EU, APAC
- Data bank - potential additional revenue generator

Exits strategies opportunities

Strategic buy-out

- *NUTEK's* technology significantly enhances portfolios of major global medtech leaders
 - ✓ Surgical oncology – Siemens Healthineers, Zeiss, Philips
 - ✓ Robotics and minimally Invasive surgery – Intuitive (Da Vinci), Medtronic
 - ✓ Liquid biopsies, companion diagnostics – Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific, Siemens Healthineers.
 - ✓ Typical M&A multiples: 10× – 20×

IPO path

IPO option post market presence and recognition

Data monetization potential

Proprietary in-vivo spectral database

Funding ask

NUTEK is raising 6m USD in SAFE to fund key milestones over 14 months

Activity	Details	M USD
Breast cancer detection algorithm	Human breast cancer Ex-Vivo & Algorithms	1.25
Complete probe electronic design	Electronic system, embedded software	1
In-Vivo prototype units	Industrial / human- factor, Opto-mechanical design, R&D units manufacturing, final software	2
Functional Rainbow system	Rainbow Probe V2, In-Vivo human Breast Cancer trial	1.75
	TOTAL	6

Potential complimentary resources

Matching investors – \$ 750 K (subject to med tech investor participation)

FFG Grant -- \$ 1 M (2nd year program subject to application renewal and matching funds)

- Including debt repayment
- Funding to date – 1.78 M\$



Dov Cohen

CEO

dov@nutekmedtech.com

THANK YOU